References
- Radkevich-Brown O, Piechocki MP, Back JB, Weise AM, Pilon-Thomas S, Wei WZ. Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression. Cancer Immunol Immunother 2010; 59:409-17; PMID:19730859; http://dx.doi.org/10.1007/s00262-009-0760-1
- Veenstra J, Gibson HM, Littrup PJ, Reyes JD, Cher ML, Takashima A, Wei WZ. Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates Her2/neu immunity. Cancer Res 2014; 74:5409-20; PMID:25092895; http://dx.doi.org/10.1158/0008-5472.CAN-14-0501
- Gibson H, Munns S, Freytag SO, Barton K, Veenstra J, Bettahi I, Wei WZ. Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors. Oncoimmunology 2015; PMID:25340006; http://dx.doi.org/10.4161/2162402X.2014.984523
- Freytag SO, Stricker H, Lu M, Elshaikh M, Aref I, Pradhan D, Levin K, Kim JH, Peabody J, Siddiqui F et al. Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2014; 89:268-76; PMID:24837889; http://dx.doi.org/10.1016/j.ijrobp.2014.02.034
- Barton KN, Paielli D, Zhang Y, Koul S, Brown SL, Lu M, Seely J, Kim JH, Freytag SO. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther 2006; 13:347-56; PMID:16290236; http://dx.doi.org/10.1016/j.ymthe.2005.10.005
- Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M et al. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 2007; 15:1016-23; PMID:17375076; http://dx.doi.org/10.1038/mt.sj.6300120
- Freytag SO, Barton KN, Zhang Y. Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene Ther 2013; 20:1131-9; PMID:23842593; http://dx.doi.org/10.1038/gt.2013.40
- Jacob JB, Kong YM, Meroueh C, Snower DP, David CS, Ho YS, Wei WZ. Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory T cells. Cancer Res 2007; 67:7020-7; PMID:17638915; http://dx.doi.org/10.1158/0008-5472.CAN-06-4755
- Jacob JB, Quaglino E, Radkevich-Brown O, Jones RF, Piechocki MP, Reyes JD, Weise A, Amici A, Wei WZ. Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Cancer Res 2010; 70:119-28; PMID:20048073; http://dx.doi.org/10.1158/0008-5472.CAN-09-2554
- Peng DJ, Zeng M, Muromoto R, Matsuda T, Shimoda K, Subramaniam M, Spelsberg TC, Wei WZ, Venuprasad K. Noncanonical K27-linked polyubiquitination of TIEG1 regulates Foxp3 expression and tumor growth. J Immunol 2011; 186:5638-47; PMID:21471442; http://dx.doi.org/10.4049/jimmunol.1003801